IV Haloperidol for the Treatment of Headache in the ED

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Single center, double-blind, randomized, placebo-controlled trial evaluating analog pain scores in patients who present to the emergency department (ED) with a complaint of headache. A total of 150 patients age 13-55 presenting to the emergency department with headache will be enrolled from October 2015 - October 2016. Patients will be randomized and pain scores and side effects will be recorded at 0, 30, 60, and 90 minutes. Follow-up will be performed by telephone at 24 hours.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Western Michigan University School of Medicine
• Treatments: Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• Emergency Department patients that complain of headache or migraine

• Males and females age 13-55

• English is primary language

Exclusion Criteria:

• Abnormal blood pressure (>200/100)

• Sudden rapid onsent (normal to worst pain in minutes)

• Fever

• Trauma

• Any history of masses, strokes, head injury or other causes of abnormal anatomy

• QT greater than 450 ms on EKG

• Allergy to Haldon

• Any altered mental status (GCS <15)

• Pregnancy

• Any abnormalities on neurologic exam

• Any clinician concern that would require CT scan of brain

• Any prisoner or ward of state